3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
2
Sarcoma
1
Conditions
Sarcoma
4
Glioblastoma
2
Central Nervous System Neoplasms
2
Brain Neoplasms
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Radiation Injuries
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Parotid Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Parathyroid Neoplasms
1
Interventions
Cyclophosphamide
4
Sirolimus
3
pembrolizumab
2
fludarabine
2
etoposide phosphate
2
Mesna
2
Melphalan
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Celecoxib
2
Busulfan
2
ripretinib
1
repotrectinib
1
pegylated granulocyte colony-stimulating factor
1
interferon gamma-1b
1
fludarabine phosphate
1
bintrafusp alfa protein, human
1
Vorinostat
1
Ursodeoxycholic Acid
1
Topotecan
1
Thrombopoietin
1
Thiotepa
1
Therapeutics
1
Tetrahydrouridine
1
Stem Cell Transplantation
1
Simvastatin
1
Radiotherapy, Image-Guided
1
Radiation
1
Psychiatric Rehabilitation
1
Plicamycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Germ Cell and Embryonal
×
Immunotherapy
×
Sarcoma
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled